Combio

CombiO is an Israeli biotechnology company focused on the discovery and development of synergistic drug combinations for the treatment of cancer. Spun out from Tel Aviv University, the company utilizes a proprietary high-throughput screening platform that combines RNA interference (RNAi) with advanced lipid nanoparticle (LNP) delivery systems to identify optimal therapeutic pairings. By targeting multiple pathways simultaneously, CombiO aims to overcome drug resistance and improve clinical outcomes in hard-to-treat malignancies such as ovarian cancer and mantle cell lymphoma. The company's approach leverages the expertise of its founders in nanomedicine and RNA therapeutics to create a pipeline of precision oncology treatments.